Drug intelligence / Profile preview

KL-HIV-Tri01

Development stage: Phase 1
Lead developer: The Affiliated Hospital of Guangdong Medical University
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
Administration: Injection

Overview

KL-HIV-Tri01 is a trispecific antibody gene therapy being investigated for the treatment of HIV-1 infection. It expresses triple targets antibodies with broad HIV-1 neutralizing activity. The drug is being evaluated in HIV-1 infected adults who are on antiretroviral therapy (ARV) in an open-label, non-randomized, uncontrolled, dose-escalation pilot study. The clinical trial includes 52 weeks of safety observation with a potential extension for long-term safety evaluation over 5 years.

Targets

CD3 (T-cell surface glycoprotein CD3)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on KL-HIV-Tri01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KL-HIV-Tri01.

Explore the full profile